Safety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women

References

• UNAIDS. The Gap Report; 2014 [cited 2015 Dec 21]. Available from: http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdf
   Google Scholar
• Drake AL, Wagner A, Richardson B, et al. Incident HIV during pregnancy and postpartum and risk of mother-to-child HIV transmission: a systematic review and meta-analysis. Plos Med. 2014;11(2):e1001608.
   PubMed Web of Science ®Google Scholar
• De Schacht C, Hoffman HJ, Mabunda N, et al. High rates of HIV seroconversion in pregnant women and low reported levels of HIV testing among male partners in Southern Mozambique: results from a mixed methods study. Plos One. 2014;9(12):e115014.
   PubMed Web of Science ®Google Scholar
• Keating MA, Hamela G, Miller WC, et al. High HIV incidence and sexual behavior change among pregnant women in Lilongwe, Malawi: implications for the risk of HIV acquisition. Plos One. 2012;7(6):e39109.
   PubMed Web of Science ®Google Scholar
• Kinuthia J, Richardson BA, Drake AL, et al. Sexual behavior and vaginal practices during pregnancy and postpartum: implications for HIV prevention strategies. JAIDS J Acquir Immune Defic Syndr. 2017;74(2):142–149.
   PubMed Web of Science ®Google Scholar
• Nel A, Mabude Z, Smit J, et al. HIV incidence remains high in KwaZulu-Natal, South Africa: evidence from three districts. Plos One. 2012;7(4):e35278.
   PubMed Web of Science ®Google Scholar
• Peltzer K, Mlambo G. Sexual HIV risk behaviour and associated factors among pregnant women in Mpumalanga, South Africa. BMC Pregnancy Childbirth. 2013;13:57.
   PubMed Web of Science ®Google Scholar
• Richardson K, Weinberg A. Dynamics of regulatory T-cells during pregnancy: effect of HIV infection and correlations with other immune parameters. Plos One. 2011;6(11):e28172.
   PubMed Web of Science ®Google Scholar
• Sheffield JS, Wendel GD Jr., McIntire DD, et al. The effect of progesterone levels and pregnancy on HIV-1 coreceptor expression. Reprod Sci. 2009;16(1):20–31.
   PubMed Web of Science ®Google Scholar
• Truong HM, Sim MS, Dillon M, et al. Correlation of immune activation during late pregnancy and early postpartum with increases in plasma HIV RNA, CD4/CD8 T cells, and serum activation markers. Clin Vaccine Immunol. 2010;17(12):2024–2028.
   PubMed Web of Science ®Google Scholar
• Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.
   PubMed Web of Science ®Google Scholar
• Baeten JM, Heffron R, Kidoguchi L, et al. Integrated delivery of antiretroviral treatment and pre-exposure prophylaxis to HIV-1–serodiscordant couples: a prospective implementation study in Kenya and Uganda. Plos Med. 2016;13(8):e1002099.
   PubMed Web of Science ®Google Scholar
• Murnane PM, Celum C, Mugo N, et al. Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial. AIDS. 2013;27(13):2155–2160.
   PubMed Web of Science ®Google Scholar
• Thomson KA, Baeten JM, Mugo NR, et al. Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women. Curr Opin HIV AIDS. 2016;11(1):18–26.
   PubMed Web of Science ®Google Scholar
• De Clercq E, Sakuma T, Baba M, et al. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res. 1987;8(5–6):261–272.
   PubMed Web of Science ®Google Scholar
• Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004;43(9):595–612.
   PubMed Web of Science ®Google Scholar
• Mirochnick M, Taha T, Kreitchmann R, et al. Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life. JAIDS J Acquir Immune Defic Syndr. 2014;65(1):33–41. DOI:10.1097/QAI.0b013e3182a921eb
   PubMed Web of Science ®Google Scholar
• Mugwanya KK, Hendrix CW, Mugo NR, et al. Pre-exposure prophylaxis use by breastfeeding HIV-uninfected women: a prospective short-term study of antiretroviral excretion in breast milk and infant absorption. Plos Med. 2016;13(9):e1002132.
   PubMed Web of Science ®Google Scholar
• Flynn PM, Mirochnick M, Shapiro DE, et al. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants. Antimicrob Agents Chemother. 2011;55(12):5914–5922.
   PubMed Web of Science ®Google Scholar
• Best BM, Burchett S, Li H, et al. Pharmacokinetics of tenofovir during pregnancy and postpartum. HIV Med. 2015;16(8):502–511.
   PubMed Web of Science ®Google Scholar
• Colbers AP, Hawkins DA, Gingelmaier A, et al. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women. Aids. 2013;27(5):739–748.
   PubMed Web of Science ®Google Scholar
• Mugwanya KK, Wyatt C, Celum C, et al. Reversibility of glomerular renal function decline in HIV-uninfected men and women discontinuing emtricitabine-tenofovir disoproxil fumarate pre-exposure prophylaxis. J Acquir Immune Defic Syndr. 2016;71(4):374–380.
   PubMed Web of Science ®Google Scholar
• Mugwanya KK, Wyatt C, Celum C, et al. Changes in glomerular kidney function among HIV-1–uninfected men and women receiving emtricitabine–tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial. JAMA Intern Med. 2015;175(2):246–254.
   PubMed Web of Science ®Google Scholar
• Mulligan K, Glidden DV, Anderson PL, et al. Effects of emtricitabine/tenofovir on bone mineral density in HIV-negative persons in a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2015;61(4):572–580.
   PubMed Web of Science ®Google Scholar
• Kasonde M, Niska RW, Rose C, et al. Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana. Plos One. 2014;9(3):e90111.
   PubMed Web of Science ®Google Scholar
• Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–2090.
   PubMed Web of Science ®Google Scholar
• Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–434.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration.Truvada approved to reduce the risk of sexually transmitted HIV in people who are not infected with the virus; 2012 [cited 2015 Sep 12]. Available from: http://www.fda.gov/downloads/ForConsumers/ConsumerUpdates/UCM311828.pdf
   Google Scholar
• World Health Organization. Guideline on When To Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis For HIV; 2015 Sep [cited 2015 Oct 27]. Available from: http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/
   Google Scholar
• Consensus Committee SAHCS. Southern African guidelines for the safe use of pre-exposure prophylaxis in men who have sex with men who are at risk for HIV infection. Southern African Journal of HIV Medicine. 2012. [cited 2017 Mar 03]. Available from: http://www.sajhivmed.org.za/index.php/hivmed/article/view/136.
   Google Scholar
• Celen MK, Mert D, Ay M, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. World J Gastroenterol. 2013;19(48):9377–9382.
   PubMed Web of Science ®Google Scholar
• Chen HL, Lee CN, Chang CH, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology. 2015;62(2):375–386.
   PubMed Web of Science ®Google Scholar
• Greenup AJ, Tan PK, Nguyen V, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol. 2014;61(3):502–507.
   PubMed Web of Science ®Google Scholar
• Pan CQ, Duan Z, Dai E, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med. 2016;374(24):2324–2334.
   PubMed Web of Science ®Google Scholar
• Samadi Kochaksaraei G, Castillo E, Osman M, et al. Clinical course of 161 untreated and tenofovir-treated chronic hepatitis B pregnant patients in a low hepatitis B virus endemic region. J Viral Hepat. 2016;23(1):15–22.
   PubMed Web of Science ®Google Scholar
• Mirochnick M, Thomas T, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother. 2009;53(3):1170–1176.
   PubMed Web of Science ®Google Scholar
• Mugo NR, Hong T, Celum C, et al. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial. Jama. 2014;312(4):362–371.
   PubMed Web of Science ®Google Scholar
• Mofenson LM, Baggaley RC, Mameletzis I. Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding. Aids. 2017;31(2):213–232.
   PubMed Web of Science ®Google Scholar
• Jao J, Abrams EJ, Phillips T, et al. In utero tenofovir exposure is not associated with fetal long bone growth. Clin Infect Dis. 2016;62(12):1604–1609.
   PubMed Web of Science ®Google Scholar
• Liotta G, Floridia M, Andreotti M, et al. Growth indices in breastfed infants pre and postnatally exposed to tenofovir compared with tenofovir-unexposed infants. Aids. 2016;30(3):525–527.
   PubMed Web of Science ®Google Scholar
• Ransom CE, Huo Y, Patel K, et al. Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy. J Acquir Immune Defic Syndr. 2013;64(4):374–381.
   PubMed Web of Science ®Google Scholar
• Siberry GK, Williams PL, Mendez H, et al. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. Aids. 2012;26(9):1151–1159.
   PubMed Web of Science ®Google Scholar
• Gibb DM, Kizito H, Russell EC, et al. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. Plos Med. 2012;9(5):e1001217.
   PubMed Web of Science ®Google Scholar
• Wang L, Kourtis AP, Ellington S, et al. Safety of tenofovir during pregnancy for the mother and fetus: a systematic review. Clin Infect Dis. 2013;57(12):1773–1781.
   PubMed Web of Science ®Google Scholar
• Sibiude J, Mandelbrot L, Blanche S, et al. Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11). Plos Med. 2014;11(4):e1001635.
   PubMed Web of Science ®Google Scholar
• Fowler MG, Qin M, Fiscus SA, et al. Benefits and risks of antiretroviral therapy for perinatal HIV prevention. N Engl J Med. 2016;375(18):1726–1737.
   PubMed Web of Science ®Google Scholar
• Lockman S, Creek T. Acute maternal HIV infection during pregnancy and breast-feeding: substantial risk to infants. J Infect Dis. 2009;200(5):667–669.
   PubMed Web of Science ®Google Scholar
• Effect of breastfeeding on infant and child mortality due to infectious diseases in less developed countries: a pooled analysis. WHO collaborative study team on the role of breastfeeding on the prevention of infant mortality. Lancet. 2000;355(9202):451–455.
   PubMedGoogle Scholar
• Sankar MJ, Sinha B, Chowdhury R, et al. Optimal breastfeeding practices and infant and child mortality: a systematic review and meta-analysis. Acta Paediatr. 2015;104(467):3–13.
   PubMed Web of Science ®Google Scholar